Every Form 4 that ADC Therapeutics SA (ADCT) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow ADCT and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ADCT filings page.
Zaki Mohamed reported acquisition or exercise transactions in this Form 4 filing.
ADC Therapeutics SA Chief Medical Officer Zaki Mohamed received an equity award in the form of restricted stock units. On June 30, 2026 he was granted 213,900 RSUs, each representing the right to receive one common share at no purchase price.
The RSUs will vest on the earlier of June 30, 2027 or a qualifying termination without cause or for good reason, provided he remains employed through the vesting date. Following this grant, Mohamed holds 896,317 common shares directly, highlighting that this is a compensation-related award rather than an open-market share purchase or sale.
GRAHAM PETER J reported acquisition or exercise transactions in this Form 4 filing.
ADC Therapeutics disclosed that Chief Legal Officer Peter J. Graham received an award of 221,100 restricted stock units (RSUs) of common shares on June 30, 2026 under an incentive award letter agreement. The RSUs vest on the earlier of June 30, 2027 or certain termination events, subject to continued employment. Each RSU represents a right to receive one common share, bringing his direct holdings to 841,640 common shares after the award.
ADC Therapeutics reported that its Chief Financial Officer, Jose Carmona, received an award of 203,700 restricted stock units on June 30, 2026. These RSUs vest on the earlier of June 30, 2027 or certain qualifying termination events, assuming continued employment. Each RSU converts into one common share, bringing his direct holdings to 938,076 common shares after the award.
MALLIK AMEET reported acquisition or exercise transactions in this Form 4 filing.
ADC Therapeutics SA reported that Chief Executive Officer Ameet Mallik received an equity compensation award in the form of 675,000 restricted stock units on June 30, 2026. These RSUs vest upon the earlier of June 30, 2027 or certain qualifying terminations of employment, conditioned on continued service. Following the grant, Mallik directly holds 2,121,769 common shares.
ADC Therapeutics SA director Robert Azelby reported routine equity compensation and related tax withholding. On June 1, 2026, he received a grant of 45,000 Common Share RSUs under the 2019 Equity Incentive Plan for his service as a director, vesting at the earlier of one year from grant or the 2027 annual meeting. On June 3, 2026, 12,600 Common Shares were withheld by the company at $3.08 per share to satisfy tax obligations from previously vested RSUs. After these transactions, Azelby directly holds 112,805 Common Shares.
ADC Therapeutics SA director Ron Squarer reported routine equity compensation and related tax withholding. On June 1, 2026, he received an annual grant of 45,000 restricted stock units for board service under the 2019 Equity Incentive Plan, with each RSU representing one common share upon vesting.
On June 3, 2026, 15,196 common shares were withheld by the company to cover his tax obligations when previously granted RSUs vested, at a reference price of $3.08 per share. After these transactions, he holds 123,431 common shares directly.
ADC Therapeutics director Sandor Victor reported routine equity compensation and related tax withholding. On June 1, 2026, he received 45,000 Common Shares through a grant of restricted stock units under the 2019 Equity Incentive Plan at a stated price of $0.00 per share. These RSUs vest on the earlier of one year from grant or the 2027 Annual Meeting of Shareholders, subject to continued board service. On June 3, 2026, the company withheld 12,600 Common Shares at $3.08 per share to cover his tax obligations upon vesting of previously granted RSUs, a non-market, tax-withholding disposition rather than an open-market sale. After these transactions, Victor directly owns 140,686 Common Shares of ADC Therapeutics.
ADC Therapeutics SA director Viviane Monges reported routine equity compensation and related tax withholding. She was granted 45,000 restricted stock units for her service as a director under the company’s 2019 Equity Incentive Plan, with each unit representing one common share.
In a separate transaction tied to the vesting of previously granted restricted share units, 2,596 common shares were withheld by the company to satisfy her tax withholding obligations at a price of $3.08 per share. After these transactions, she directly owns 186,447 common shares. These events reflect compensation and tax mechanics, not open-market share purchases or sales.
ADC Therapeutics SA director Peter Hug reported routine equity compensation activity. On June 1, 2026, he received a grant of 45,000 Common Shares in the form of restricted stock units (RSUs) under the company’s 2019 Equity Incentive Plan for service as a director.
The RSUs vest on the earlier of one year from the grant date or the date of the 2027 Annual Meeting of Shareholders, subject to his continued service. On June 3, 2026, 2,156 Common Shares were withheld by the company to satisfy his tax withholding obligations upon vesting of previously granted RSUs, a non-market, tax-related disposition rather than an open-market sale.
Following these transactions, Hug directly holds 263,344 Common Shares of ADC Therapeutics SA.
ADC Therapeutics SA director Jean-Pierre Bizzari received an annual grant of 45,000 restricted stock units (RSUs) under the company’s 2019 Equity Incentive Plan for board service. The RSUs vest on the earlier of one year from the grant date or the 2027 annual shareholder meeting, and each RSU converts into one common share.
To cover tax withholding on previously vested RSUs, the company withheld 12,600 common shares at $3.08 per share. After these compensation-related transactions, Bizzari directly holds 139,302 common shares.
ADC Therapeutics SA director Timothy Coughlin reported routine equity compensation activity. On June 1, 2026, he received an annual grant of 45,000 common shares in the form of restricted stock units under the company’s 2019 Equity Incentive Plan for service as a director.
On June 3, 2026, 12,600 common shares were withheld by the company to cover his tax obligations when previously granted restricted share units vested. This tax withholding is shown as a disposition but is not an open‑market sale. After these transactions, he directly holds 72,400 common shares.
ADC Therapeutics SA major shareholder entities managed by Redmile Group reported significant open-market sales of common stock. Across March 31–April 2, 2026, they sold a combined 5,880,415 shares in multiple transactions at weighted average prices around $3.28–$3.80 per share.
After the last reported trades, one line of indirect holdings shows 12,666,731 shares and one line of direct holdings shows 10,265,297 shares of common stock. The footnotes state that these securities are directly owned by private investment vehicles, including RedCo II Master Fund, L.P., managed by Redmile Group, LLC, and may be deemed beneficially owned by Redmile and by Jeremy Green as Redmile’s principal, with beneficial ownership disclaimed beyond their pecuniary interest.
ADC Therapeutics SA reported that Chief Accounting Officer Lisa Michelle Kallebo received a grant of 62,900 Common Shares on February 13, 2026 as a restricted share unit award valued at $3.99 per share. These shares vest in three equal installments: one-third on the first anniversary of the grant date and one-third on each of the following two anniversaries, subject to continued service. On the same date, 5,433 Common Shares were withheld by the company at $3.99 per share to cover her tax obligations from previously vesting restricted share units. After these transactions, she directly owned 128,224 Common Shares.
ADC Therapeutics SA Chief Medical Officer Receives Equity Award
ADC Therapeutics SA granted Chief Medical Officer Zaki Mohamed an award covering 285,200 Common Shares on February 13, 2026. According to the footnotes, these shares will be delivered upon settlement of restricted share units that vest one-third on the first anniversary of the grant date and one-third on each anniversary thereafter, subject to continued service.
On the same date, 24,603 Common Shares were withheld by the company to cover Mr. Mohamed’s tax withholding obligations related to previously granted restricted share units that vested. After these transactions, he directly owned 682,417 Common Shares.
ADC Therapeutics SA reported that Chief Legal Officer Peter J. Graham received a grant of 294,800 Common Shares on February 13, 2026, valued at $3.99 per share. These shares relate to a restricted share unit award that vests in three equal annual installments beginning on the first anniversary of the grant date, subject to continued service.
The company also withheld 33,294 Common Shares at $3.99 per share to cover Mr. Graham’s tax obligations upon vesting of previously granted restricted share units, which is a non‑market tax-withholding disposition rather than an open-market sale. Following these transactions, Mr. Graham directly holds 620,540 Common Shares.
ADC Therapeutics SA Chief Financial Officer Jose Carmona reported equity-related transactions in company common shares. He was granted 271,600 common shares at $3.99 per share as part of a restricted share unit award that vests in three equal annual installments starting on February 13, 2027, contingent on continued service. To cover tax withholding from the vesting of previously granted restricted share units, 25,880 common shares were withheld by the company at $3.99 per share. After these transactions, Carmona directly holds 734,376 common shares.
ADC Therapeutics SA reported that Chief Executive Officer Ameet Mallik acquired 900,000 Common Shares on February 13, 2026 as part of a restricted share unit award valued at $3.99 per share. According to a footnote, these shares will be delivered over time as the RSUs vest: one-third on the first anniversary of the February 13, 2026 grant date and one-third on each of the next two anniversaries, subject to continued service.
On the same date, 103,231 Common Shares were disposed of through a tax-withholding transaction at $3.99 per share to cover Mr. Mallik’s tax obligations related to previously granted RSUs vesting. After these transactions, he directly held 1,446,769 Common Shares. A separate indirect holding of 669,101 Common Shares is reported as held by a grantor retained annuity trust, and Mr. Mallik disclaims beneficial ownership of those shares except to the extent of his pecuniary interest.
ADC Therapeutics SA reported a routine insider equity transaction by its Chief Executive Officer and director, Ameet Mallik. On 12/06/2025, 233,146 common shares were withheld by the company at a price of $3.29 per share to cover his tax obligations arising from the vesting of previously granted restricted share units. After this tax-withholding event, Mallik beneficially owns 1,319,101 common shares directly. This type of Form 4 event reflects administrative handling of equity compensation rather than an open‑market purchase or sale.
ADC Therapeutics SA reported an insider equity transaction involving its Chief Medical Officer, Mohamed Zaki. On 12/06/2025, the company withheld 41,068 common shares at a price of $3.29 per share to cover his tax withholding obligations tied to previously granted restricted share units that vested. After this automatic withholding, Zaki beneficially owns 421,820 common shares, held directly. This type of transaction reflects routine share withholding for taxes rather than an open-market sale.
ADC Therapeutics SA's Chief Accounting Officer reported a routine share transaction under Form 4. On 12/06/2025, the officer had 7,140 common shares disposed of at $3.29 per share, coded as an "F" transaction. This represents shares withheld by the company to cover tax obligations related to the vesting of previously granted restricted share units.
After this withholding event, the officer directly beneficially owns 70,757 common shares of ADC Therapeutics SA. The filing reflects administrative tax settlement activity rather than an open-market buy or sell decision.
ADC Therapeutics SA reported an insider transaction by Chief Legal Officer Peter Graham. On 12/06/2025, the company withheld 49,508 common shares at a price of $3.29 per share to cover his tax obligations arising from the vesting of previously granted restricted share units. After this withholding, Graham beneficially owns 359,034 common shares directly. The filing notes that this is a routine tax withholding transaction rather than an open‑market sale, and no derivative securities transactions were reported.
ADC Therapeutics SA's Chief Financial Officer, Jose Carmona, reported a routine share withholding related to equity compensation. On 12/06/2025, the company withheld 53,236 common shares to cover his tax obligations arising from the vesting of previously granted restricted share units. The shares were valued at $3.29 per share for this tax withholding event.
After this transaction, Carmona beneficially owned 488,656 common shares, held directly. The filing is a standard Form 4 disclosure of insider equity activity rather than an open-market purchase or sale.
ADC Therapeutics (ADCT): RedCo II Master Fund, L.P., affiliated with Redmile Group, reported the purchase of 3,846,153 pre-funded warrants in a private placement that closed on October 27, 2025. The filing shows a transaction code P (purchase).
The purchase price per pre-funded warrant was $3.90, reflecting the common share price minus the exercise price. The warrants carry an exercise price of CHF 0.08 per share (approximately $0.10 based on the October 12, 2025 exchange rate) and are exercisable any time after closing until the tenth anniversary, subject to a 9.99% beneficial ownership blocker. Each warrant is exercisable for one common share, for a total underlying 3,846,153 common shares.
The filing notes Redmile Group, LLC and Jeremy Green may be deemed beneficial owners through management of RedCo II, with beneficial ownership disclaimed except to the extent of pecuniary interest.